Mutant p53: an oncogenic transcription factor
- 2 April 2007
- journal article
- review article
- Published by Springer Science and Business Media LLC in Oncogene
- Vol. 26 (15), 2212-2219
- https://doi.org/10.1038/sj.onc.1210296
Abstract
Inactivation of tumor-suppressor genes is one of the key hallmarks of a tumor. Unlike other tumor-suppressor genes, p53 is inactivated by missense mutations in half of all human cancers. It has become increasingly clear that the resulting mutant p53 proteins do not represent only the mere loss of wild-type p53 tumor suppressor activity, but gain new oncogenic properties favoring the insurgence, the maintenance, the spreading and the chemoresistance of malignant tumors. The actual challenge is the fine deciphering of the molecular mechanisms underlying the gain of function of mutant p53 proteins. In this review, we will focus mainly on the transcriptional activity of mutant p53 proteins as one of the potential molecular mechanisms. To date, the related knowledge is still quite scarce and many of the raised questions of this review are yet unanswered.This publication has 75 references indexed in Scilit:
- S100A2 gene is a direct transcriptional target of p53 homologues during keratinocyte differentiationOncogene, 2006
- Intrinsic tumour suppressionNature, 2004
- Post-translational modification of p53 in tumorigenesisNature Reviews Cancer, 2004
- Live or let die: the cell's response to p53Nature Reviews Cancer, 2002
- Analysis of JNK, Mdm2 and p14ARF contribution to the regulation of mutant p53 stabilityJournal of Molecular Biology, 2000
- Regulation of p53 stability by Mdm2Nature, 1997
- Mdm2 promotes the rapid degradation of p53Nature, 1997
- Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic MutationsScience, 1994
- Different Tumor-Derived p53 Mutants Exhibit Distinct Biological ActivitiesScience, 1990
- Mutations in the p53 gene occur in diverse human tumour typesNature, 1989